Venlafaxine oxidation in vitro is catalysed by CYP2D6-Reference-Cited by-同舟云学术

Venlafaxine oxidation in vitro is catalysed by CYP2D6

Published:1996-02 Issue:2 Volume:41 Page:149-156
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

OTTON S. V.,BALL S. E.,CHEUNG S. W.,INABA T.,RUDOLPH R. L.,SELLERS E. M.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1996.tb00173.x/fullpdf

Reference37 articles.

1. The pharmacogenetics of the selective serotonin reuptake inhibitors;Brøsen;Clin Invest,1993

2. The genetic polymorphism of debrisoquine/sparteine metabolism-Clinical aspects;Eichelbaum;Pharmacol Ther,1990

3. The effect of paroxetine and other specific serotonin reuptake inhibitors on cytochrome P450IID6 activity in human liver microsomes;Crewe;Br J Clin Pharmacol,1991

4. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6-the source of the sparteine/debrisoquine polymorphism;Brørsen;Br J Clin Pharmacol,1991

5. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin;Brøsen;Ther Drug Monit,1991

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative in vitro hepatic clearances of commonly used antidepressants, antipsychotics, and anti-inflammatory agents in rainbow trout liver S9 fractions;Aquatic Toxicology;2024-09

2. Venlafaxine exposure alters mitochondrial respiration and mitomiR abundance in zebrafish brains;Environmental Toxicology and Chemistry;2024-05-02

3. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine;Archives of Pharmacal Research;2024-04-25

4. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment;Biomolecules;2024-01-12

5. Venlafaxine’s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis;Psychopharmacology;2023-10-19